LIGIA COSTA BATTAINI
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/12 - Laboratório de Pesquisa Básica em Doenças Renais, Hospital das Clínicas, Faculdade de Medicina
LIM/12 - Laboratório de Pesquisa Básica em Doenças Renais, Hospital das Clínicas, Faculdade de Medicina
8 resultados
Resultados de Busca
Agora exibindo 1 - 8 de 8
conferenceObject Dendritic Cells from X-Linked Hyper IgM Patients Present Impaired Responses to Candida Albicans and Paracoccidioides Brasiliensis That Can Be Reversed By Exogenous Soluble Cd40l(2012) MARQUES, Otavio Cabral; ARSLANIAN, Christina; RAMOS, Rodrigo Nalio; MARQUES, Mariana Morato; SCHIMKE, Lena Friederike; SOEIRO, Paulo Vitor; JANCAR, Sonia; FERREIRA, Janaira Fernandes; WEBER, Cristina Worm; KUNTZE, Gisele; ROSARIO, Nelson Augusto; CARVALHO, Beatriz Costa; BERGAMI-SANTOS, Patricia Cruz; HACKETT, Mary; OCHS, Hans; TORGERSON, Troy; BARBUTO, Jose Alexandre; CONDINO NETO, Antonio- Water removal from the legs does explain hypotension in short daily hemodialysis(2014) BALES, A. M.; BATTAINI, L. C.; NARDOTTO, L. L.; HUMEL, R. S.; SILVA, B. C.; MOYSES, R. M. A.; CASTRO, M. C. M.; ELIAS, R. M.
bookPart Avaliação clinicolaboratorial do paciente com doença renal(2016) BATTAINI, Ligia Costa; ONUSIC, Vivian LumibookPart Doença renal diabética(2022) LIRA, Aécio Lopes de Araújo; BATTAINI, Ligia Costa; QUEIROZ, Márcia Silva; ZATZ, RobertobookPart Ajuste de doses na insuficiência renal(2022) BATTAINI, Ligia Costa; ESTEVES, Gabriel Daltoso; MENESES, Jaqueline Pilon deconferenceObject Which Induction Therapy Should Be Used in Kidney Transplants with Prolonged Cold Ischemia Time?(2012) ARAUJO, M. J. C. L. N.; ONUSIC, V. L.; BATTAINI, L. C.; BARBOSA, E.; NAHAS, W. C.; CASTRO, M. C. R.With the aim to retrospectively analyze the impact of different induction therapies on transplant results of non-sensitized, first, isolated, adult, deceased kidney transplants who were submitted to cold ischemia times (CIT) ≥ 24 hours, 51 patients treated with Basiliximab (GI) were compared to 81 patients treated with Thymoglobulin (GII). Transplants were performed between Jan/2007 and July/2011. Maintenance longterm immunosuppression consisted of Tacrolimus, Mycophenolate and Prednisone in both groups. Patients treated with Thymoglobulin received CMV prophylaxis for 3 months with Gancyclovir. Demographic data are summarized in Table I. No differences were detected on recipient age and gender and brain death cause. Time on dialysis pre transplantation, donor age, donor Scr and CIT time were higher in GII. Follow-up time was longer in GI. Results were not different, except for CMV disease and are shown on Table II. Figure 1 shows the evolution of Scr over the 1st year in both groups. Demographic data GI (N= 51 ) GII (N= 81 ) p Recipient gender (M/F) 31/20 51/30 NS Recipient age (y) 49.9 49.6 NS Stroke as brain death cause (%) 64 62 NS Time on dialysis pre Tx (m) 85 184 0.02* Donor age (y) 47 53 0.02* CIT (hours) 26 28 0.01* Donor Scr (mg/dl) 1.4 1.8 0.02* * p< 0.05 Results GI (N= 51 ) GII (N= 81 ) p DGF rate (%) 67 63 NS Number of days at 1st hospitalization 19 18 NS Hospital readmission rate 0.7 (1.5/pt) 0.7 (1.4/pt) NS cute rejection rate (% ) 19 11 NS Acute rejection rate (% ) CMV rate (%) 27 13 0.04* 1y patient Survival 83 83 NS 1y graft Survival 81 79 NS * p< 0.05 In our center, patients who received kidneys with long ischemia time presented extremely high DGF rates and an impact on renal function at one year was observed. In this cohort, recipients treated with Thymoglobulin received more frequently kidneys from marginal donors with longer CIT, but the use of Thymoglobulin provided similar one year patient and graft survival and a tendency to lower acute rejection rates in these patients.conferenceObject Which Induction Therapy Should Be Used in Kidney Transplants with Prolonged Cold Ischemia Time?(2012) ARAUJO, M. J. C. L. N.; ONUSIC, V. L.; BATTAINI, L. C.; BARBOSA, E. A.; BOJIKIAN, R. T.; DAVID, D. R.; ANTONOPOULOS, I. M.; PAULA, F. Jota de; NAHAS, W. C.; NETO, E. D.; LEMOS, F. B. C.; CASTRO, M. C. Ribeiro de- Determination of Anti-Phospholipase A2 and Anti-Thrombospondin Type 1 Domain-Containing Protein 7A in Latin Patients with Membranous Nephropathy(2023) BATTAINI, Ligia C.; RANZANI, Otavio T.; MARCAL, Lia J.; ANTONANGELO, Leila; JORGE, Lecticia B.; BITENCOURT, Cristiane D.; WORONIK, Victoria; MALHEIROS, Denise M. A.; YU, LuisPrimary membranous nephropathy (MN) is caused by antibodies against podocyte antigens, especially the type M receptor of phospholipase A2 (PLA2R) and thrombospondin type-1 domain containing 7 A (THSD7A). This study's aim was the determination of anti-PLA2R, anti-THSD7A serum antibodies, and anti-PLA2R renal tissue staining prevalence in a Latin population with MN, as well as evaluating their role as biomarkers for disease activity. The performance of the two anti-PLA2R serum diagnostic methods-ELISA and indirect immunofluorescence (IFI)-was evaluated for the diagnosis of MN. Fifty-nine patients, including 29 with MN, 18 with lupus membranous nephropathy (LMN) and 12 with focal and segmental glomerulosclerosis (FSGS), were evaluated for serum antibodies. Renal biopsies were also evaluated for the presence of anti-PLA2R staining. Twenty-one patients with MN were followed for 1 year. Patients with LMN and FSGS were negative for both antibodies. All 29 MN patients were negative for anti-THSD7A; 16 MN patients were positive for anti-PLA2R by ELISA and/or IFI, and 3 MN patients were positive for anti-PLA2R only by IFI. Thus, the anti-PLA2R ELISA test demonstrated 45% sensitivity and 97% specificity, while the IFI test showed, respectively, 55% and 100% in our MN patients. Among the 28 MN renal biopsies, 20 presented anti-PLA2R positive staining, corresponding to a 72% sensitivity. Positive correlations were observed between the anti-PLA2R ELISA titer and proteinuria. In conclusion, determination of anti-PLA2R antibodies in the MN Latin population showed similar rates to those reported for other populations. The anti-PLA2R serum levels correlated with MN disease activity.